Referências
Principais artigos
Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Sep 29;45(36):3538-700.Texto completo Resumo
Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.Texto completo Resumo
Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5-67.Texto completo Resumo
Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014 Jan;59(1):220-34;e1-2.Texto completo Resumo
Artigos de referência
1. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Sep 29;45(36):3538-700.Texto completo Resumo
2. Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.Texto completo Resumo
3. Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5-67.Texto completo Resumo
4. Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 20072007 Jun;45(6):1185-91. Resumo
5. Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ. 2003Mar 15;326(7389):584-8. Resumo
6. Allison MA, Armstrong DG, Goodney PP, et al. Health disparities in peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2023 Jul 18;148(3):286-96.Texto completo Resumo
7. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 Oct 19;382(9901):1329-40. Resumo
8. Kim ESH, Arya S, Bryce Y, et al. Sex differences in peripheral vascular disease: a scientific statement from the American Heart Association. Circulation. 11 Mar 2025 [Epub ahead of print].Texto completo Resumo
9. Watson K, Watson BD, Pater KS. Peripheral arterial disease: a review of disease awareness and management. Am J Geriatr Pharmacother. 2006 Dec;4(4):365-79. Resumo
10. Abaraogu UO, Ezenwankwo EF, Dall PM, et al. Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease. PLoS One. 2018 Nov 15;13(11):e0207456.Texto completo Resumo
11. Rajagopalan S. Approach to and management of intermittent claudication. In: Rajagopalan S, Mukherjee D, Mohler ER, eds. Manual of vascular diseases. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005:70-87.
12. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999 Mar;20(5):344-53.Texto completo Resumo
13. Youssef F, Gupta P, Mikhailidis DP, et al. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology. 2005 May-Jun;56(3):279-87. Resumo
14. Paraskevas KI, Papas TT, Pavlidis P, et al. The importance of conservative measures in peripheral arterial disease: an update. Angiology. 2008 Oct-Nov;59(5):529-33. Resumo
15. Ostchega Y, Paulose-Ram R, Dillon CF, et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007 Apr;55(4):583-9. Resumo
16. Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004 Dec;40(6):1158-65. Resumo
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837-53. Resumo
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Nov 7;352(9139):1558. Resumo
19. Andersen CA, Roukis TS. The diabetic foot. Surg Clin North Am. 2007 Oct;87(5):1149-77;x. Resumo
20. Clement DL, De Buyzere ML, Duprez DA. Hypertension in peripheral arterial disease. Curr Pharm Des. 2004;10(29):3615-20. Resumo
21. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015 Apr 24;116(9):1509-26. Resumo
22. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997 Jul 1;96(1):44-9. Resumo
23. Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012 Oct 24;308(16):1660-7. Resumo
24. Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev. 2013;(12):CD003075.Texto completo Resumo
25. Thomas Manapurathe D, Krishna SM, Dewdney B, et al. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: a meta-analysis of randomised controlled trials. PLoS One. 2017 Jun 2;12(6):e0178713.Texto completo Resumo
26. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145-53.Texto completo Resumo
27. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003 Feb 11;107(5):753-6.Texto completo Resumo
28. Harris SK, Roos MG, Landry GJ. Statin use in patients with peripheral arterial disease. J Vasc Surg. 2016 Dec;64(6):1881-8. Resumo
29. Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007;(4):CD000123.Texto completo Resumo
30. Stoekenbroek RM, Boekholdt SM, Fayyad R, et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015 Mar;101(5):356-62. Resumo
31. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004 Aug 10;110(6):738-43. Resumo
32. Lane R, Harwood A, Watson L, et al. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017;(12):CD000990.Texto completo Resumo
33. Serra R, Bracale UM, Ielapi N, et al. The impact of chronic kidney disease on peripheral artery disease and peripheral revascularization. Int J Gen Med. 2021 Jul 23;14:3749-59.Texto completo Resumo
34. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998 Feb 10;97(5):425-8.Texto completo Resumo
35. Andras A, Stansby G, Hansrani M. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev. 2013;(7):CD003285.Texto completo Resumo
36. Wang H, Wu P, Jiang D, et al. Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a dose-response meta-analysis. Eur J Med Res. 2022 Nov 21;27(1):261.Texto completo Resumo
37. Małecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century - a new face of disease. Atherosclerosis. 2009 Oct;206(2):328-34. Resumo
38. Esfahani F, Rooholamini SA, Azadeh B, et al. Arterial fibrodysplasia: a regional cause of peripheral occlusive vascular disease. Angiology. 1989 Feb;40(2):108-13. Resumo
39. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646.Texto completo Resumo
40. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1223-49.Texto completo Resumo
41. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-337.Texto completo Resumo
42. Mangione CM, Barry MJ, Nicholson WK, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022 Aug 23;328(8):746-53.Texto completo Resumo
43. US Preventive Services Task Force; Davidson KW, Barry MJ, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022 Apr 26;327(16):1577-84.Texto completo Resumo
44. American College of Radiology. ACR appropriateness criteria: management of iliac artery occlusive disease. 2024 [internet publication].Texto completo
45. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004 Jul 28;292(4):453-61.Texto completo Resumo
46. National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. Dec 2020 [internet publication].Texto completo
47. Paraskevas KI, Kotsikoris I, Koupidis SA, et al. Ankle-brachial index: a marker of both peripheral arterial disease and systemic atherosclerosis as well as a predictor of vascular events. Angiology. 2010 Aug;61(6):521-3. Resumo
48. American College of Radiology. ACR appropriateness criteria: lower extremity arterial claudication - imaging assessment for revascularization. 2022 [internet publication].Texto completo
49. American College of Radiology. ACR appropriateness criteria: sudden onset of cold, painful leg. 2023 [internet publication].Texto completo
50. Depalma RG. Impotence in vascular disease: relationship to vascular surgery. Br J Surg. 1982 Jun;69(suppl):S14-S16. Resumo
51. Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014 Jan;59(1):220-34;e1-2.Texto completo Resumo
52. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000 Jan;31(1 Pt 2):S1-296. Resumo
53. TASC Steering Committee; Jaff MR, White CJ, Hiatt WR, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). Vasc Med. 2015 Oct;20(5):465-78. Resumo
54. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo Resumo
55. Anand SS, Bosch J, Eikelboom JW, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):219-29.Texto completo Resumo
56. Smolderen KG, Ujueta F, Buckley Behan D, et al. Understanding the pain experience and treatment considerations along the spectrum of peripheral artery disease: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. 2025 Mar;18(3):e000135.Texto completo Resumo
57. Razavi MK, Lee DS, Hofmann LV. Catheter-directed thrombolytic therapy for limb ischemia: current status and controversies. J Vasc Interv Radiol. 2004 Jan;15(1 Pt 1):13-23. Resumo
58. Broderick C, Patel JV. Infusion techniques for peripheral arterial thrombolysis. Cochrane Database Syst Rev. 2021 Nov 17;11:CD000985.Texto completo Resumo
59. Robertson I, Kessel DO, Berridge DC. Fibrinolytic agents for peripheral arterial occlusion. Cochrane Database Syst Rev. 2013 Dec 19;(12):CD001099.Texto completo Resumo
60. Guidon M, McGee H. Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989-2008) review. Eur J Cardiovasc Prev Rehabil. 2010 Apr;17(2):140-54. Resumo
61. Mays RJ, Hiatt WR, Casserly IP, et al. Community-based walking exercise for peripheral artery disease: an exploratory pilot study. Vasc Med. 2015 Aug;20(4):339-47. Resumo
62. Mangiafico RA, Fiore CE. Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies. Curr Vasc Pharmacol. 2009 Jul;7(3):394-413. Resumo
63. National Institute for Health and Care Excellence. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. May 2011 [internet publication].Texto completo
64. Pande RL, Hiatt WR, Zhang P, et al. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med. 2010 Jun;15(3):181-8.Texto completo Resumo
65. Brown T, Forster RB, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2021 Jun 30;6(6):CD003748.Texto completo Resumo
66. Warner CJ, Greaves SW, Larson RJ, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. 2014 Jun;59(6):1607-14. Resumo
67. Iida O, Yokoi H, Soga Y, et al; STOP-IC investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013 Jun 11;127(23):2307-15.Texto completo Resumo
68. De Backer T, Vander Stichele R, Lehert P, et al. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. BMJ. 2009 Mar 10;338:b603Texto completo Resumo
69. Stevens JW, Simpson E, Harnan S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99:1630-1638. Resumo
70. Fakhry F, Fokkenrood HJ, Spronk S, et al. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev. 2018 Mar 8;(3):CD010512.Texto completo Resumo
71. Malgor RD, Alahdab F, Elraiyah TA, et al. A systematic review of treatment of intermittent claudication in the lower extremities. Vasc Surg. 2015 Mar Mar;61(3 Suppl):54S-73S. Resumo
72. Kamoen V, Vander Stichele R, Campens L, et al. Propionyl-L-carnitine for intermittent claudication. Cochrane Database Syst Rev. 2021 Dec 26;12(12):CD010117.Texto completo Resumo
73. Nicolaï SP, Kruidenier LM, Bendermacher BL, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2013;(6):CD006888.Texto completo Resumo
74. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2013;(2):CD004001.Texto completo Resumo
75. Liu Y, Xu Y, Fang F, et al. Therapeutic efficacy of stem cell-based therapy in peripheral arterial disease: a meta-analysis. PLoS One. 2015 Apr 29;10(4):e0125032. Resumo
76. Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies. Circ Res. 2017 Apr 14;120(8):1326-40. Resumo
77. Bachoo P, Thorpe PA, Maxwell H, et al. Endovascular stents for intermittent claudication. Cochrane Database Syst Rev. 2010;(1):CD003228.Texto completo Resumo
78. Chowdhury MM, McLain AD, Twine CP. Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev. 2014;(6):CD006767.Texto completo Resumo
79. Nguyen BN, Amdur RL, Abugideiri M, et al. Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015 Jun;61(6):1489-94. Resumo
80. Reifsnyder T, Arhuidese IJ, Hicks CW, et al. Contemporary outcomes for open infrainguinal bypass in the endovascular era. Ann Vasc Surg. 2016 Jan;30:52-8. Resumo
81. Bedenis R, Lethaby A, Maxwell H, et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. 2015;(2):CD000535.Texto completo Resumo
82. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004.Texto completo Resumo
83. Debus ES, Nehler MR, Govsyeyev N, et al. Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial. Circulation. 2021 Oct 5;144(14):1104-16.Texto completo Resumo
84. Abu Dabrh AM, Steffen MW, Asi N, et al. Bypass surgery versus endovascular interventions in severe or critical limb ischemia. J Vasc Surg. 2016 Jan;63(1):244-53.Texto completo Resumo
85. Hsu CC, Kwan GN, Singh D, et al. Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia. Cochrane Database Syst Rev. 2018 Dec 8;(12):CD009195.Texto completo Resumo
86. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019 Nov-Dec;13(6):860-72.Texto completo Resumo
87. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024 Jan 2;149(1):e1-56.Texto completo Resumo
88. Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Feb 9;77(5):629-58.Texto completo Resumo
89. Basili S, Raparelli V, Vestri A, et al. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost. 2010 Apr;103(4):766-73. Resumo
90. Li L, Geraghty OC, Mehta Z, et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017 Jul 29;390(10093):490-9. Resumo
91. Kayssi A1, Al-Atassi T, Oreopoulos G, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2016;(8):CD011319.Texto completo Resumo
92. Antoniou GA, Georgiadis GS, Antoniou SA, et al. Bypass surgery for chronic lower limb ischaemia. Cochrane Database Syst Rev. 2017;(4):CD002000.Texto completo Resumo
93. Abu Dabrh AM, Steffen MW, Asi N, et al. Nonrevascularization-based treatments in patients with severe or critical limb ischemia. J Vasc Surg. 201 Nov;62(5):1330-9. Resumo
94. Paraskevas KI, Mikhailidis DP. Angiogenesis: a promising treatment option for peripheral arterial disease. Curr Vasc Pharmacol. 2008Apr;6(2):78-80. Resumo
95. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease: meta-analysis and systematic review of the literature. Atherosclerosis. 2010 Mar;209(1):10-7. Resumo
96. Moazzami B, Mohammadpour Z, Zabala ZE, et al. Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev. 2022 Jul 8;7:CD008347.Texto completo Resumo
97. Teraa M, Sprengers RW, van der Graaf Y, et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg. 2013 Dec;258(6):922-9. Resumo
98. Managed Healthcare Executive. FDA approves first drug-coated angioplasty balloon catheter. Oct 2014 [internet publication].Texto completo
99. US Food and Drug Administration. Medtronic IN.PACT Admiral paclitaxel-coated PTA balloon catheter - P140010. Dec 2014 [internet publication].Texto completo
100. Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015 Jul 9;373(2):145-53.Texto completo Resumo
101. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015 Feb 3;131(5):495-502.Texto completo Resumo
102. Kayssi A, Al-Jundi W, Papia G, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries. Cochrane Database Syst Rev. 2019 Jan 26;(1):CD012510.Texto completo Resumo
103. Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018 Dec 18;7(24):e011245.Texto completo Resumo
104. US Food and Drug Administration. UPDATE: treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality. Aug 2019 [internet publication].
105. Medicines and Healthcare products Regulatory Agency. Paclitaxel coated devices (PCD) used in the treatment of peripheral arterial disease: update to previous MHRA guidance on use. Feb 2024 [internet publication].Texto completo
106. Gryka RJ, Buckley LF, Anderson SM. Vorapaxar: the current role and future directions of a novel protease-activated receptor antagonist for risk reduction in atherosclerotic disease. Drugs R D. 2017 Mar;17(1):65-72. Resumo
107. Tepe G, Brodmann M, Werner M, et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the randomized Disrupt PAD III trial. JACC Cardiovasc Interv. 2021 Jun 28;14(12):1352-61.Texto completo Resumo
108. Tepe G, Brodmann M, Bachinsky W, et al. Intravascular lithotripsy for peripheral artery calcification: mid-term outcomes from the randomized Disrupt PAD III trial. J Soc Cardiovasc Angiogr Interv. 2022 Jul-Aug;1(4):100341.Texto completo Resumo
109. National Institute for Health and Care Excellence. Intravascular lithotripsy for calcified arteries in peripheral arterial disease. Jan 2024 [internet publication].Texto completo
110. Davies MG. Criticial limb ischemia: epidemiology. Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):10-4. Resumo
111. Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021 Oct 14;42(39):4013-24.Texto completo Resumo
112. Aday AW, Gutierrez JA. Antiplatelet therapy following peripheral arterial interventions: the choice is yours. Circ Cardiovasc Interv. 2020 Aug;13(8):e009727.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal